Lung Cancer Considered

The 2026 World Conference on Lung Cancer brought together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2026 in world languages. In this episode, host Dr. Narjust Florez moderates a discussion in Spanish about breakthrough advances in thoracic oncology presented at the conference with Dr. Jorge Alatorre Alexander and Dr. Miguel Gonzalez Velez. Guests: Jorge Alatorre Alexander, MD Head of the Medical Oncology Service National Institute of Respiratory Diseases (INER) Miguel Gonzalez Velez, MD Medical Oncologist John Theurer Cancer Center at Hackensack University Medical Center

The 2026 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2026 in world languages. In this episode, host Dr. Clarissa Mathias moderates a discussion in Portuguese about breakthrough advances in thoracic oncology presented at the conference with Dr. Lilian Faroni and Dr. Vladmir Cordeiro de Lima. Guests: Lilian Faroni, MD, PhD Radiation Oncologist Oncologia D'Or Rio de Janeiro, Brazil Vladmir Cordeiro de Lima, MD, PhD Thoracic and Breast Oncologist A.C. Camargo Cancer Center, São Paulo, Brazil

In this special WCLC 2026 episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu recap key findings from day three of the conference, featuring major advances that move targeted therapies earlier in the treatment of lung cancer. Guests Dr. Julia Rotow, Dr. Roy Herbst, and Dr. Daniel Tan discuss new data from DESTINY-Lung04, ADAURA, and REZILIENT3 and what these findings could mean for clinical practice. Guests: Dr. Julia Rotow Clinical Director and Research Director, Lowe Center for Thoracic Oncology Dana-Farber Cancer Institute Dr. Roy Herbst Director, Dartmouth Cancer Center Professor, Geisel School of Medicine at Dartmouth Dr. Daniel Shao-Weng Tan Senior Consultant Medical Oncologist at Division of Medical Oncology, National Cancer Centre Singapore Professor, Duke-NUS Medical School Senior Clinician-Scientist, Genome Institute of Singapore

The 2026 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2026 in world languages. In this episode, host Dr. Chunxia Su moderates a discussion in Mandarin Chinese about breakthrough advances in thoracic oncology presented at the conference with Dr. Zhengfei Zhu, Dr. Yun Fan, and Dr. Dongsheng Yue. Guests: Dr. Yun Fan, MD, PhD Chief Expert of the Multidisciplinary Lung Cancer Team, Zhejiang Cancer Hospital; Senior Consultant (Grade II Chief Physician); Doctoral Supervisor Dr. Dongsheng Yue, MD, PhD Tianjin Medical University Cancer Institute and Hospital Dr. Zhengfei Zhu, MD, PhD Department of Radiation Oncology Fudan University Shanghai Cancer Center

In this special WCLC 2026 episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu discuss daily highlights from the conference and ask what changes in clinic on Monday. A ROS1 drug that protects the brain and a first line combination that could not beat a decade old standard. Dr. Alexander Drilon brings the first line ARROS-1 data on zidesamtinib, and Dr. Giannis Mountzios walks us through EVOKE-03, sacituzumab govitecan plus pembrolizumab in PD-L1 high lung cancer. Guests: Alexander Drilon, MD Chief, Early Drug Development Service Memorial Sloan Kettering Cancer Center Professor, Weill Cornell Medical College Attending Physician, Thoracic Oncology Service Giannis Mountzios, MD, MSc, PhD Medical Oncologist and Director at the 4th Oncology Department and Clinical Trials Unit Henry Dunant Hospital Center Athens, Greece,

From the IASLC 2026 World Conference on Lung Cancer (WCLC) in Seoul, Dr. Narjust Florez talks with Dr. Chad Rusthoven about MAVERICK, the trial that tested MRI surveillance alone against prophylactic cranial irradiation in small cell lung cancer, and with Dr. Chul Kim about the final overall survival results of PAPILLON, amivantamab plus chemotherapy in EGFR exon 20 insertion NSCLC. Both guests share what patients and community oncologists should take from the data. Guests: Chul Kim, MD, MPH Thoracic Medical Oncologist and Associate Professor Georgetown University Chad G. Rusthoven, MD Adjunct Associate Professor University of Colorado University of North Carolina at Chapel Hill

Get ready for WCLC 2026 in Seoul with Lung Cancer Considered hosts Dr. Stephen Liu and Dr. Narjust Florez. From preparing for the flight and beating jet lag to navigating COEX, networking, exploring Seoul's food scene, and making the most of the meeting, they share practical tips to help attendees arrive prepared and enjoy the full WCLC experience.

In this episode, Dr. Narjust Florez is joined by Dr. Yasir Elamin and Dr. Liliana Faroni to explore the evolving management of oligometastatic lung cancer. They break down key definitions, discuss when and how to use consolidative therapies like radiation and surgery, and examine patient selection, limitations, and emerging tools such as ctDNA that are shaping a more precise approach to care. Guests: Yasir Elamin, MD Associate Professor of Thoracic Medical University of Texas MD Anderson Cancer Center Liliana Faroni, MD, PhD Radiation Oncologist, Oncologia D'Or Rio de Janeiro

In this Korean-language episode of Lung Cancer Considered, Dr. Chul Kim is joined by Dr. Hye-Ryun Kim and Dr. Young Kwang Chae to discuss the evolving role of immunotherapy across the lung cancer treatment continuum. They explore perioperative strategies for resectable NSCLC, treatment selection and biomarkers in advanced disease, emerging research, and what they are looking forward to at WCLC 2026 in Seoul. Guest Host: Chul Kim, MD, MPH Thoracic Medical Oncologist and Associate Professor Georgetown University Guests: Hye Ryun Kim, MD, PhD Medical Oncologist Chief of Lung Cancer Center Yonsei Cancer Center Young Kwang Chae, MD, MPH, MBA Professor, Division of Hematology Oncology, Department of Medicine Northwestern University Feinberg School of Medicine

Host Dr. Stephen Liu is joined by José Luis Castro, WHO Director-General Special Envoy for Chronic Respiratory Diseases, for a thought-provoking discussion on why lung cancer must be recognized as a global health priority. They explore the challenges of raising awareness, reducing stigma, expanding equitable access to lung cancer screening and care, and advancing the policies and partnerships needed to improve outcomes worldwide. The conversation also offers a preview of Castro's keynote message ahead of his appearance at the 2026 World Conference on Lung Cancer (WCLC) in Seoul this September. Guest: José Luis Castro World Health Organization (WHO) Director-General Special Envoy for Chronic Respiratory Diseases

In this episode of Lung Cancer Considered, host Dr. Narjust Florez is joined by Dr. Mark Lewis and Dr. Michael Maddaus for a candid conversation about physician wellness, burnout, grief, and resilience. Drawing from their personal and professional experiences, they explore the hidden emotional toll of caring for patients with cancer, the limitations of the “just be more resilient” mindset, and the importance of self-compassion, vulnerability, and seeking support. Dr. Mark Lewis is Director of Gastrointestinal Oncology at Intermountain Health. He has become a leading voice on physician well-being, patient-centered care, and the emotional realities of oncology practice. Dr. Michael Maddaus is a cardiovascular and thoracic surgeon at the University of Minnesota.

As part of IASLC's ongoing series of Lung Cancer Considered podcasts in world languages, Dr. Molly Li moderates a discussion in Cantonese with Dr. Tony Mok, Dr. Chao Zhang, and Dr. Wen-Zhao Zhong. The discussion reviews advances in ALK+ non-small cell lung cancer (NSCLC).

Thymic epithelial tumors are rare but complex thoracic cancers that require specialized diagnosis and multidisciplinary management. In this episode of Lung Cancer Considered, Dr. Stephen Liu is joined by Dr. Nicolas Girard and Dr. Erica Pietroluongo to discuss the diagnosis, staging, and treatment of thymoma and thymic carcinoma, including current standards of care, evolving systemic therapies, and promising areas of research. They also highlight the importance of international collaboration in advancing care for patients with these rare malignancies. Guests: Nicolas Girard, MD, PhD Head of the Thorax Institute Curie Montsouris, Institut Curie, Paris, France Erica Pietroluongo, MD, PhD Medical Oncologist, University Federico II, Naples Visiting Scholar, University of Chicago

Patients with ROS1-positive NSCLC have a new treatment option following the FDA approval of zidesamtinib for those previously treated with a ROS1 tyrosine kinase inhibitor. In this episode, Dr. Stephen Liu, Dr. Alexander Drilon, and Dr. Rosario Charo Garcia Campelo discuss the ARROS1 trial results, the drug's efficacy and safety profile, CNS activity, and where zidesamtinib may fit into current and future treatment strategies for ROS1-positive lung cancer. Guests: Alexander Drilon, MD Chief, Early Drug Development Service Attending Physician, Thoracic Oncology Service Memorial Sloan Kettering Cancer Center Professor, Weill Cornell Medical College Rosario Charo Garcia Campelo, MD Head of Medical Oncology and Thoracic Tumor Unit, Chair, University Hospital Head of the Oncology Research Group, Biomedical Research Institute A Coruna Spain

How could cellular therapies and cancer vaccines transform the future of treatment for ALK-positive lung cancer? Host Dr. Narjust Florez sits down with Dr. Vincent Lam and Dr. Carmen Mecca to explore the latest research, the science driving these innovative approaches, and what these advances could mean for patients and the future of precision oncology. Key Topics Covered: • ALK-positive lung cancer • Cellular Therapy • Vaccines Guests: Vincent Lam, MD Associate Professor of Oncology, Johns Hopkins University School of Medicine Director, Thoracic Oncology Clinical Research Program Sidney Kimmel Comprehensive Cancer Center Carmen Mecca. PhD Postdoctoral Fellow, Chiarle Lab Department of Pathology Boston Children's Hospital

Starting your first faculty position can be both exciting and overwhelming. In this episode of Lung Cancer Considered, host Dr. Narjust Florez is joined by Dr. Arthi Sridhar to discuss the transition from fellowship to independent practice, sharing practical insights on navigating clinical responsibilities, building professional relationships, balancing personal and professional priorities, and developing a sustainable career in oncology. Whether you're beginning a career in academic or community practice, this conversation offers actionable advice to help you thrive in your early years as faculty. Guests: Arthi Sridhar, MD - Arthi.Sridhar@UTSouthwestern.edu Assistant Professor, Department of Internal Medicine Harold C. Simmons Comprehensive Cancer Center UT Southwestern Medical Center

In this episode of Lung Cancer Considered, Dr. Balazs Halmos reflects on a career at the forefront of thoracic oncology, sharing the pivotal moments, lessons learned, and hard truths that have shaped modern lung cancer care. Guest: Balazs Halmos, MD, MS Professor of Medicine Associate Director, Clinical Science Montefiore Einstein Comprehensive Cancer Center

This episode of Lung Cancer Considered provide a preview of the upcoming IASLC 2026 World Conference on Lung Cancer in Seoul, South Korea this September. Key topics covered include WCLC26 highlights - Multidisciplinary, WCLC26 deadlines and information about Seoul. Guests: Myung-Ju Ahn, MD, PhD Distinguished Professor Section of Hematology-Oncology, Department of Medicine Hanyang University Medical Center, Hanyang University School of Medicine Seoul, Republic of Korea Vincent Wentao Fang, MD Professor, Department of Thoracic Surgery Shanghai East Hospital Tongji University Medical School Jiraporn Setakornnukul, MD, PhD Radiation Oncologist, Associate Professor Division of Radiation Oncology Department of Radiology Faculty of Medicine, Siriraj Hospital Mahidol University Bangkok, Thailand Yasushi Yatabe, MD, PhD Chief, Department of Diagnostic Pathology, National Cancer Center Hospital Chief, Division of Molecular Pathology, National Cancer Center Research Institute National Cancer Center Japan

In Part 2 of the ASCO 2026 Highlights series, hosts Dr. Narjust Florez and Dr. Stephen Liu are joined by Dr. Julie Brahmer and Dr. Solange Peters to discuss some of the most notable immunotherapy advances presented at the 2026 ASCO Annual Meeting. The conversation explores emerging data for PD-1/VEGF and PD-L1/VEGF bispecific antibodies, the growing role of antibody-drug conjugates in combination with immunotherapy, and promising new strategies targeting KRAS-mutant lung cancers, highlighting how these approaches may reshape the future treatment landscape. Guests: Julie R. Brahmer, MD, MSc, FASCO, FAIO The Marilyn Meyerhoff Professor of Thoracic Oncology Co-Leader, Cancer Immunology Research Program Co-Director, Upper Aerodigestive Cancers Program Director, Johns Hopkins Kimmel Cancer Center, Bayview Campus Professor Solange Peters, MD, PhD Chair of Medical Oncology Director of Oncology Department - CHUV Lausanne University Hospital

In this Part 1 of 2 ASCO 2026 Highlights episodes, hosts Dr. Narjust Florez and Dr. Stephen Liu are joined by Dr. Alice Shaw and Dr. Jonathan Goldman to review some of the most impactful targeted therapy data presented at the 2026 ASCO Annual Meeting. The discussion explores the practice-changing LIBRETTO-432 trial in early-stage RET-positive NSCLC, long-term outcomes with lorlatinib in ALK-positive disease, emerging data for neladalkib, and promising results for sunvozertinib in EGFR exon 20 insertion–positive NSCLC, highlighting how these findings may influence treatment decisions across disease stages. Guests: Dr. Alice Shaw. is a Professor of Medicine at Harvard Medical School, Chair of Medical Oncology, and a thoracic oncologist at Dana Farber Cancer Institute. She is widely recognized as a pioneer in the field of ALK-positive non-small cell lung cancer, having led landmark clinical trials that established crizotinib, ceritinib, and lorlatinib as standards of care. Dr. Jonathan W. Goldman is a Professor of Medicine and thoracic oncologist at the UCLA David Geffen School of Medicine, where he serves as a principal investigator in the Phase I drug development program. Dr. Goldman has been at the forefront of early-phase oncology trials across multiple tumor types, with a particular focus on novel therapeutics in lung cancer, and he was the presenting author of Libretto 432 at the plenary session at the 2026 ASCO

In this episode of Lung Cancer Considered, host Dr. Narjust Florez is joined by Natalie Brown and Dr. Aurora Lucas to explore how patients and caregivers are using artificial intelligence in the context of lung cancer care. The discussion highlights real-world experiences, addressing both the benefits of AI in improving understanding and empowerment, and the risks of misinformation, overreliance, and lack of personalization. The conversation also offers practical guidance for patients, families, and clinicians on using AI responsibly while reinforcing the importance of partnership with the care team. Guests: Aurora Lucas, EdD Lung Cancer Patient Advocate Natalie S. Brown, MBA Lung Cancer Advocate & Speaker Founder, Beyond The Diagnosis LLC

As part of IASLC's ongoing series of podcasts in world languages, Dr. Alfredo Addeo moderates a Virtual Tumor Board discussion with Dr. Andrea Fillipi and Dr. Piergiorgio Solli. The tumor board focuses on the management of resectable EGFR-mutant NSCLC. Host: • Alfredo Addeo, MD Head of Oncology Service University Hospital Geneva Guests: Andrea R. Filippi, MD Head of Radiation Oncology, Fondazione Istituto Nazionale dei Tumori, Milan Associate Professor, Radiation Therapy Department of Oncology, University of Milan Piergiorgio Solli, MD, PhD Head of Thoracic Surgery IRCCS Fondazione Istituto Nazionale dei Tumori, Milan

This episode of Lung Cancer considered explores the evolving management of oligometastatic lung cancer. They break down key definitions, discuss when and how to use consolidative therapies like radiation and surgery, and examine patient selection, limitations, and emerging tools such as ctDNA that are shaping a more precise approach to care. Guests: Dr. Yasir Elamin is a thoracic/head and neck medical oncology fellowship director and associate professor in the department of thoracic/head and neck medical oncology at the University of Texas MD Anderson Cancer Center. Dr. Lilian Faroni is a thoracic radiation oncologist atClínica São Vicente - Oncologia D'Orfrom Rio de Janeiro, Brazil. She specializes in the care of patients with oligometastatic lung cancer from oligopersistent to oligoprogressive disease.

In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses KRAS updates from the American Association for Cancer Research (AACR) 2026 Annual Meeting with Dr. Deborah Doroshow, Dr. David S. Hong, and Dr. Jonathan Riess. Guests: Deborah Doroshow, MD, PhD Associate Professor of Medicine, Hematology/Oncology Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai David S. Hong, MD Douglas E. Johnson Endowed Professor Deputy Chair, Department of Investigational Cancer Therapeutics [A Phase I Program] Division of Cancer Medicine Clinical Medical Director, Clinical and Translational Research Center The University of Texas MD Anderson Cancer Center Jonathan Riess, MD Associate Professor of Medicine, UC Davis Comprehensive Cancer Center Director of Thoracic Oncology, University of California, Davis

This episode of Lung Cancer Considered, part of IASLC's World Language Series, features host Dr. Narjust Florez leading a Spanish-language discussion with Dr. José Corona-Cruz and Dr. Diego Carrillo on perioperative chemoimmunotherapy in early-stage lung cancer. Using a real-world case, they explore clinical decision-making, biomarker considerations, and surgical challenges, with a focus on implementation barriers in Latin America. The conversation highlights multidisciplinary strategies and practical insights to optimize care in resource-variable settings.

This episode of LCC covers the work of our nursing and allied health professional committee and, most importantly, highlight their role in the care of patients with thoracic malignancies. Guests: Professor Nicole Kiss is a Fellow of Dietitians Australia and Clinical Associate Professor in the Institute for Physical Activity and Nutrition at Deakin University. Nicole co-leads the Exercise and Nutrition for Cancer research group, with her research focused on early identification of cancer-related muscle loss and improving access to treatment. Dr. Morten Quist is a former IASLC Board member and is currently an Associate Professor and Research Physiotherapist at the University Hospital of Copenhagen, Rigshospitalet. For the past 25 years, he has pioneered clinical exercise-based rehabilitation for people living with cancer, with a primary focus on exercise, prehabilitation, and rehabilitation in lung cancer. His work bridges research, clinical care, patient advocacy, and voluntary engagement – always with patient wellbeing at the center.

This episode of Lung Cancer Considered covers lung cancer in India and brings awareness about its first and largest advocacy group in the nation. To learn more about Lung Connect India, key members of the team will share how the organization began and the work they have done to improve the care of patients with lung cancer in the region. Guest: Vandana Mahajan, Lead Counselor for Lung Connect India, brings a unique and inspiring voice shaped by her dedication to supporting patients and families affected by lung cancer, and her commitment to driving conversations that matter from prevention and early detection to treatment advances and survivorship. Sanjeev Sharma, the Director & CEO of Lung Connect India, an initiative dedicated to improving awareness, access, and advocacy in lung cancer care. With a strong commitment to patient-centered innovation, he works to bridge gaps between patients, caregivers, clinicians, and policymakers, advancing meaningful dialogue and practical solutions to improve lung cancer outcomes

As part of IASLC's ongoing podcast series in world languages, Dr. Chul Kim moderates a discussion in Korean with Dr. Beung-Chul Ahn and Dr. Hyein Jeon. The session focuses on the clinical management of EGFR-mutant non-small cell lung cancer (NSCLC) through a case-based discussion. Guests:

In this episode, recorded in Mandarin, host Dr. Chunxia Su leads a discussion about early stage and preoperative care for patients with NSCLC with an EGFR mutation. Guests: Wenzhao Zhong, Deputy Prensendent of Guangdong Provincial People's Hospital, Director of the Cancer Institute, Guangdong Provincial People's Hospital Jie Hu， Deputy director, Department of Respiratory Medicine, Shanghai Geriatric Medical Center，Zhongshan Hospital, Fudan University Min Fan M D， Deputy Director , Department of Radiation Oncology, Fudan University Shanghai Cancer Center

In this episode of Lung Cancer Considered, host Dr. Narjust Florez conducts three mock molecular tumor boards with Dr. Misako Nagasaka and Dr. Biagio Ricciuti, live from the Targeted Therapies of Lung Cancer (TTLC) 2026 conference. The discussion addresses the question, “How do we get the right molecular answer, at the right time, for the right patient?” Guests: Misako Nagasaka, MD, PhD Associate Clinical Professor University of California, Irvine Biagio Ricciuti, MD, PhD Thoracic Medical Oncologist, Dana-Farber Cancer Institute Faculty, Harvard School of Medicine

In this episode of Lung Cancer Considered, host Dr. Narjust Florez and guest Dr. Sam Rosner examine controversies around antibody-drug conjugates (ADCs) live from the 2026 Targeted Therapies of Lung Cancer (TTLC) conference. Guest: Sam Rosner, MD Assistant Professor of Medicine, University of Maryland School of Medicine Thoracic Medical Oncologist, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center

As part of IASLC's ongoing series of podcasts in world languages, Dr. Alfredo Addeo moderates a Virtual Tumor Board discussion with Dr. Angela Botticella and Dr. Jean Yannis Perentes. The tumor board focuses on the management of resectable EGFR-mutant NSCLC. Guests: Angela Botticella, MD Radiational Oncologist Department of Radiation Oncology Gustave Roussy Jean Yannis Perentes, MD, PhD Professor and Chief, Department of Thoracic Surgery University Hospital of Lausanne CHUV

In this episode of Lung Cancer Considered, host Dr. Stephen Liu is joined by Dr. Sara Pilotto and Dr. Jonathan Riess for a virtual tumor board discussion on the management of metastatic EGFR exon 19 NSCLC . Using a complex case featuring discordant biomarker results and brain metastases, the panel explores first-line treatment strategies including osimertinib monotherapy, FLAURA2 (osimertinib plus chemotherapy), and MARIPOSA (amivantamab plus lazertinib), as well as sequencing at progression, re-biopsy, CNS considerations, and the evolving role of local consolidation and clinical trials.

In this episode of Lung Cancer Considered, host Dr. Narjust Florez explores controversies in managing lung cancer patients with comorbidities – those often underrepresented in clinical trials – with Dr. Hina Khan and Dr. Corey Langer, live from the Targeted Therapies of Lung Cancer (TTLC) 2026 conference. The discussion examines treatment decision-making in patients with ECOG performance status 2, renal dysfunction, advanced age, and complex comorbid conditions, emphasizing careful phenotyping, geriatric assessment, and individualized risk–benefit evaluation. The episode also highlights the balance between efficacy, toxicity, quality of life, and patient goals when treating the patients most commonly seen in clinical practice. Guests: Hina Khan, MD Thoracic Oncologist Assistant Professor of Medicine Warren Alpert Medical School, Brown University Corey Langer, MD, FACP Director, Thoracic Oncology, Abramson Cancer Center Professor of Medicine , Perelman School of Medicine University of Pennsylvania

In this episode of Lung Cancer Considered, host Dr. Narjust Florez explores the evolving landscape of emerging molecular targets in NSCLC with Dr. Kelsey Pan and Rajat Thawani, live from the Targeted Therapies of Lung Cancer (TTLC) 2026 conference. The discussion highlights rare oncogenic drivers with a focus on clinical evidence, resistance mechanisms and trial design. The episode also addresses biomarker testing, the role of next-generation sequencing and liquid biopsy, and what the next five years may hold for precision treatment strategies in NSCLC. Guests: Kelsey Pan, MD, MPH Assistant Professor of Medicine Department of Hematology & Oncology, Thoracic Medical Oncology Section Emory University Winship Cancer Institute Rajat Thawani, MD Assistant Professor of Medicine Division of Hematology and Oncology Knight Cancer Institute, OHSU

This episode of Lung Cancer Considered focuses on a case of a patient with extensive stage SCLC. SCLC is a highly lethal subtype of lung cancer, accounting for about 13% of new lung cancer diagnoses with high variability based on geography and socioeconomic factors. The standard treatment for ES-SCLC had been platinum + etoposide for several decades, but over the past 7 years, we have had several new paradigm shifts that have led to real survival gains. To discuss current state of the art management, Guests: Raffaele Califano, Consultant at the Christie and Professor of Medical Oncology at Manchester University in the United Kingdom. Dr. Jessica Menis, thoracic medical oncologist at University Hospital of Verona, in Verona, Italy

This episode examines the role public policy plays in impacting lung cancer treatment and research. The world has made tremendous progress in the treatment of lung cancer over the past decade, and much of that progress is the result of supportive public health policies. As we look to the future, healthcare policy is sure to play an even bigger role in further improving patient outcomes, but many challenging barriers exist on a global scale. Host: Dr. Stephen Liu Guests: Professor Andreas Charalambous, Chair of the Department of Nursing and Professor of Oncology and Palliative Care at the Cyprus University of Technology. Professor Nicole Rankin, Head of the Evaluation and Implementation Science Unit at the Melbourne School of Population and Global Health of the University of Melbourne Dr. Samuel Kareff, thoracic medical oncologist at the Eugene M. and Christine E. Lynn Cancer Institute and Clinical Assistant Professor at Florida Atlantic University

As part of IASLC's ongoing series of Lung Cancer Considered podcasts in world languages, Dr. Molly Li moderates a discussion in Cantonese with two expert cardiothoracic surgeons, Dr. Ben Li, Professor from The First Affiliated Hospital of Guangzhou Medical University and, and Dr. Calvin Ng, Professor from the Chinese University of Hong Kong. The discussion: reviews surgical management of early-stage NSCLC, including VATS, and lobar versus sublobar resection; and explores novel technologies including endobronchial therapy and tubeless anesthesia. Host: Molly Li, MD Clinical Assistant Professor Department of Clinical Oncology, CUHK, Hong Kong Guests: Shuben Li, MD, PhD Professor, Department of Thoracic Surgery National Center for Respiratory Medicine The First Affiliated Hospital of Guangzhou Medical University Calvin S.H. Ng, BSc MBBS, MD Environmental Foundation Professor of Thoracic Surgery Department of Surgery The Chinese University of Hong Kong (CUHK)

This episode of Lung Cancer Considered examines how artificial intelligence is being incorporated into patient care and what the future holds for this emerging technology. We will be discussing: • Is AI the right move for oncology care? • What is the impact on patient care and our patient expert's experience? • And how can we learn more about AI? Guest: Dr. Sandip Patel, is a professor of Medicine at UCSD and a nationally recognized leader in precision cancer medicine and innovation. He specializes in early-phase clinical trials and immunotherapy, with a focus on developing innovative treatments for patients with advanced lung cancer. Today, we're excited to welcome him to the podcast to discuss the future of AI in cancer care, in general, and in thoracic oncology in particular.

This episode of Lung Cancer Considered, hosted by Dr. Narjust Florez, examines the challenges of delivering lung cancer care in areas affected by war and displacement with guests Dr. Julie Gralow and Dr. Rafal Dziadziuszko. The discussion addresses disrupted diagnosis and treatment, heightened inequities, and unique environmental exposures that may increase lung cancer risk in conflict settings. The episode also highlights emerging opportunities through global collaboration, adaptable care models, and shared responsibility across the oncology community. Guests: Dr. Julie Gralow, Chief Medical Officer and Executive Vice President of the American Society of Clinical Oncology (ASCO). She is also the founder of the Women's Empowerment Cancer Advocacy Network (WE CAN) and an expert in global oncology. Rafał Dziadziuszko, M.D., Ph.D., professor of medicine, Head, Department of Oncology & Radiotherapy and Early Phase Clinical Trials Centre, Medical University of Gdańsk in Poland

As part of IASLC's ongoing series of Lung Cancer Considered podcast episodes in world languages, Dr. Ece Cali moderates a discussion in Turkish with Dr. Irfan Çiçin and Dr. Fulden Yumuk. The episode is part of our Virtual Tumor Board series and focuses on immunotherapy for non-small cell lung cancer (NSCLC).

This episode reviews the IASLC 2025 Hot Topic in Basic and Translational Science Conference, which focused on unraveling precancer and early-stage lung cancer, a theme that really captures where the field is heading. Instead of reacting to advanced disease. Guests: Dr. Triparna Sen, a professor of Internal Medicine at The Ohio State University and the director of the Lung Cancer Preclinical Therapeutics Platform at the OSUCCC – James. She also serves as the associate director of research for the Division of Medical Oncology. Her research focuses on understanding and therapeutically targeting mechanisms of therapy resistance and lineage plasticity in lung cancer, with a primary emphasis on small cell lung cancer (SCLC) and biologically aggressive subsets of non-small cell lung cancer. Dr. Aaron Tan is a physician-scientist whose work bridges early detection, translational biology, and clinical relevance in lung cancer. Dr. Tan is a Medical Oncologist at the National Cancer Centre Singapore (NCCS), where he is involved in early drug development, genomics with a focus on EGFR mutated lung cancer, and clinical implementation of liquid biopsy including for advanced lung cancer and MRD in early-stage lung cancer.

As part of IASLC's Lung Cancer Considered World Language Series, guest host Dr. Maria Cecilia Mathias leads a discussion in Portuguese about the junior faculty perspective with Dr. Maria Thereza Starling and Dr. Paula Duarte.

In this episode of Lung Cancer Considered, host Dr. Stephen Liu is joined by CNN Medical Correspondent Meg Tirrell and WTOP reporter Neal Augenstein to discuss the role of the media in lung cancer awareness and perception. Traditional media, including television and radio, do much to shape the public perception of lung cancer and healthcare in general. Meg Tirrell and Neal Augenstein share their experiences reporting in the health sector, establishing trust with their audiences in the face of uncertainty, and distilling complex medical information to the general public.

Since the first immunotherapy agent for lung cancer was approved in 2015, this class of drugs has captured the imagination and the narrative for the treatment of driver negative lung cancer. Immunotherapy is now the standard of care for most patients with lung cancer in some form. And while not all patients benefit, those that do, have the chance for transformative benefit. In today's episode, we focus not on the benefit of immunotherapy, which can be massive, but on the toxicity of immunotherapy. Guest: Dr. Jarushka Naidoo, a consultant medical oncologist at Beaumont Hospital Dublin and a Professor in the Royal College of Surgeons in Ireland. She currently serves as national lung cancer lead for Cancer Trials Ireland and serves on several international guideline panels including ASCO and SITC

The FDA has approved subcutaneous amivantamab. Join host Dr. Narjust Florez and guests, Dr. Natasha Leighl and Dr. Federico Cappuzzo, as they explore the science and convenience factor, as well as what this shift means for patients, clinicians, and oncology practice.

In this special episode of Lung Cancer Considered, Dr. Narjust Florez and Dr. Stephen Liu discuss highlights from the IASLC | ASCO 2025 North America Conference on Lung Cancer. Dr. Igor Odintsov discusses updates in diagnostic pathology, including the integration of next-gen sequencing into the patient's journey. Dr. Byoung Chul Cho shares data from the phase 3 trial of gotistobart vs. docetaxel in patients with metastatic squamous cell lung cancer. Dr. Sulin Wu shares insights on the role of family history in lung cancer among women and low-exposure smokers.

In this episode of Lung Cancer Considered, host Dr. Stephen Liu speaks with two thoracic oncologists practicing in New Zealand—Dr. Laird Cameron from Auckland Hospital and Dr. Annie Wong from the University of Otago—about the unique challenges and approaches to lung cancer care in their island nation of 5.4 million people. The conversation explores New Zealand's healthcare coverage system, patient population characteristics including smoking rates, the current state of lung cancer screening programs, and how molecular testing is conducted for non-small cell lung cancer patients. Drs. Cameron and Wong discuss access to targeted therapies and immunotherapy, the drug approval process in New Zealand, cultural considerations and health disparities affecting lung cancer treatment, and the clinical research infrastructure available in the country. This global perspective highlights how IASLC members face different regional challenges while working toward common goals in advancing lung cancer care.

As part of IASLC's Lung Cancer Considered World Language Series, host Dr. Narjust Florez leads a Spanish-language discussion with three leaders in thoracic oncology across Latin America: Dr. Mónica Castro, Dr. Dolores de la Mata, and Dr. Maritza Ramos Ramírez. They discuss the current landscape of lung cancer in women across the region including unique risk factors and social challenges. The guests share their career paths, the barriers women face in thoracic oncology in Latin America, and their advice for the next generation entering the field.

In this episode of Lung Cancer Considered, host Dr. Stephen Liu speaks with Prof. Li Zhang and Dr. Elaine Shum about recent progress in antibody–drug conjugates (ADCs) for EGFR-mutant non-small cell lung cancer (NSCLC). They discuss new approvals of datopotamab deruxtecan (in the United States) and sacituzumab tirumotecan (in China), key findings from the TROPION and OptiTROP trials, and emerging agents. The conversation highlights the advances in efficacy, safety, and combination strategies that are shaping the evolving treatment landscape for patients with EGFR-mutant NSCLC. Guest: Li Zhang, MD Professor, Medical Oncology Department Sun Yat-Sen University Cancer Center No Social Guest: Elaine Shum, MD Assistant Professor Director of Cancer Screening Programs New York University Perlmutter Cancer Center

Join Dr. Narjust Florez as she explores complementary and integrative medicine in lung cancer care with leading experts Dr. Ting Bao, Dr. Jun J. Mao, and Dr. Lisa Davis. This episode clarifies the differences between alternative, complementary, and integrative approaches while addressing oncologists' concerns about safety and drug interactions. Learn where to find reliable information, what the research shows about treatments like acupuncture and supplements, and how patients can safely incorporate these therapies into their cancer journey. Guests: Ting Bao, MD, MS, FSIO Co-Director, Leonard P. Zakim Center for Integrative Therapies and Healthy Living Member of the Faculty, Harvard Medical School Dana-Farber Cancer Institute Jun J. Mao, MD, MSCE Chief, Integrative Medicine Service Laurance S. Rockefeller Chair in Integrative Medicine Professor of Medicine, Weill Cornell Medicine Memorial Sloan Kettering Cancer Center Lisa Davis, PharmD, FCCP, BCPS, BCOP, Clinical Professor, Pharmacy Practice & Science The University of Arizona, R. Ken Coit College of Pharmacy